JMP Securities Downgrades CTI BioPharma to Market Perform

Benzinga · 05/11/2023 09:01
JMP Securities analyst Reni Benjamin downgrades CTI BioPharma (NASDAQ:CTIC) from Market Outperform to Market Perform.